A new risk stratification strategy for fatty liver disease by incorporating MAFLD and fibrosis score in a large US population.
Ya-Cong ZhangZhang-Yan LyuBing MaLi-Min LiWei WangChao ShengHong-Ji DaiYu-Bei HuangFang-Fang SongFeng-Ju SongKe-Xin ChenPublished in: Hepatology international (2022)
Utilizing a representative sample of the US population, we proved the validity of MAFLD subtype and fibrosis score, rather than the traditional definition (NAFLD and AFLD), in the risk stratification of FLD patients. These findings may be applied to guide the determination of surveillance options for FLD patients.